ArticleBritish journal of cancer2017
Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.
Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 54 citations in OpenAlex.
- Hepatocellular carcinoma surveillance may be associated with potential psychological harms in patients with cirrhosis.Hepatology (Baltimore, Md.) · 2024Trial
- Missed Diagnosis in Alcohol-Related Hepatocellular Carcinoma: A Call for Alcohol Consumption and Liver Disease Early Detection.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Machine learning models for predicting liver cancer: a real-world cohort study in China.Frontiers in cell and developmental biology · 2026Article
- Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE.Clinical imaging · 2025Article
- Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis.Liver cancer · 2024Article
- Metabolomic Analysis of Human Cirrhosis and Hepatocellular Carcinoma: A Pilot Study.Digestive diseases and sciences · 2024Article
- Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.Nature reviews. Gastroenterology & hepatology · 2023Review
- Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review.International journal of molecular sciences · 2023Review
- Major variation in hepatocellular carcinoma treatment and outcomes in England: a retrospective cohort study.Frontline gastroenterology · 2023Article
- Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?Journal of hepatology · 2023Review
- Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD.Gastro hep advances · 2023Article
- High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence.World journal of gastroenterology · 2022Article
- Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System.Molecules (Basel, Switzerland) · 2022Article
- Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures.World journal of gastrointestinal oncology · 2021Review
- Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021Article
- The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma.Cancers · 2021Review
- Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.Cancer causes & control : CCC · 2021Article
- Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021Article
- Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis.Hepatology communications · 2020Article
- Is hepatocellular carcinoma surveillance in high-risk populations effective?Hepatic oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVariation in survival in hepatocellular carcinoma (HCC) has been attributed to different aetiologies or disease stages at presentation. While international guidelines recommend surveillance of high-risk groups to permit early diagnosis and curative treatment, the evidence that surveillance decreases disease-specific mortality is weak.
methodsWe compared HCC survival figures from Japan (n=1174) and Hong Kong (n=1675) over similar time periods (Japan 2000-2013, Hong Kong, China 2003-2014). The former has an intensive national surveillance programme, while the latter has none. We also analysed changes in survival in Japan over a 50-year period including data from before and after institution of a national HCC surveillance programme.
resultsIn Japan, over 75% of cases are currently detected by surveillance, whereas in Hong Kong <20% of cases are detected presymptomatically. Median survival was 52 months in Japan and 17.8 months in Hong Kong; this survival advantage persisted after allowance for lead-time bias. Sixty-two per cent of Japanese patients had early disease at diagnosis and 63% received curative treatment. The comparable figures for Hong Kong were 31.7% and 44.1%, respectively. These differences could not be accounted for by disease aetiology, and patients in Hong Kong who were detected at an early stage had a similar survival to the analogous patients in Japan.
conclusionsThe variation in survival is largely accounted for by stage at diagnosis, which in turn relates to the intensity of surveillance programmes and the consequent variation in curative therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.